Physician profile
Aisha Hasan
NPI 1568812873
$965.69
in general payments reported to CMS, 2019-2025
14 companies · $347 in 2025
The $347 reported for 2025 was less than what a typical Cornea and External Diseases Specialist provider received nationally (typical 2025 total: $477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2022: $110 · 2023: $99.00 · 2024: $306 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $751.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $165.99 | 2019-2023 | Clareon |
| Harrow Eye, LLC | $164.24 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $158.87 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $99.55 | 2022-2024 | Tyrvaya |
| Apellis Pharmaceuticals, INC. | $90.60 | 2024-2025 | Syfovre |
| Bausch & Lomb Americas INC. | $77.14 | 2022-2025 | Miebo, Vyzulta |
| Mallinckrodt Hospital Products INC. | $55.30 | 2025 | Acthar |
| Dompe US, INC. | $43.79 | 2024 | Oxervate |
| Medline Industries LP | $26.75 | 2024 | |
| Revance Therapeutics, INC. | $19.88 | 2025 | Daxxify |
| Coopervision INC. | $19.56 | 2023 | Paragon Crt |
| Astellas Pharma US INC | $17.00 | 2023 | Izervay |
| Kala Pharmaceuticals, INC. | $14.00 | 2022 | |
| Horizon Therapeutics Plc | $13.02 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aisha Hasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.